5. References

  1. IBM Micromedex® DRUGDEX® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www-micromedexsolutions-com.libproxy.uthscsa.edu/ (cited: June 2, 2023).
  2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2023. Available at: http://clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed June 2, 2023.
  3. Donepezil hydrochloride transdermal patch (Adlarity®) package insert. Corium, LLC. March 2022.
  4. Donepezil tablets, orally disintegrating tablets (Aricept®, Aricept® ODT) Package Insert. Eisai Inc., November 2022.
  5. Galantamine extended-release capsules package insert. Aurobindo Pharma Limited. November 2022.
  6. Galantamine film coated oral tablet package insert. Aurobindo Pharma Limited. August 2021.
  7. Galantamine hydrobromide oral solution package insert. Hikma Pharmaceuticals USA, Inc. March 2022.
  8. Rivastigmine transdermal system (Exelon® Patch) package insert.  Novartis, December 2020.
  9. Rivastigmine tartrate oral capsules package insert. Alembic Pharmaceuticals, Inc. April 2022.
  10. Memantine extended-release/donepezil capsules (Namzaric®) package insert. Allergan USA, Inc., January 2019.
  11. Battle CE, Abdul-Rahim AH, Shenkin SD, et al. Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev. 2021 Feb 22;2(2):CD013306.
  12. Hershey LA, Coleman-Jackson R. Pharmacological management of dementia with lewy bodies. Drugs Aging. 2019;36(4):309-319.
  13. Kim JO, Lee SJ, Pyo JS. Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: A meta-analysis. PLoS One. 2020 Feb 7;15(2):e0227820.
  14. Cotter J, Muhlert N, Talwar A, et. al. Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2018;86:99-107.